RxDoctor Payments Data

Triet Huynh, MD

Pain Medicine · Pasadena, TXNPI 1255365698

Payments from drug & device makers

$4,135in general payments, 2019–2025

Across 114 payments — averaging $36.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$952
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$366
  • Saluda Medical Americas, Inc.$263
  • Collegium Pharmaceutical, Inc.$217
  • Scilex Pharmaceuticals Inc.$146
  • plus $713 from 21 others

What the payments were for

  • Travel & lodging$1,67340%
  • Food & beverage$2,46160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,135 in reported general payments places this provider in the 55th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$72,954
Medicare patients
92
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl30$58,685
Xtampza ErOxycodone Myristate48$27,487
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen729$21,757
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen102$3,878
Gabapentin275$3,221
MovantikNaloxegol Oxalate18$3,208
Morphine Sulfate ErMorphine Sulfate75$2,206
Fentanyl34$1,974
Tizanidine Hcl160$1,845
Lidocaine11$1,666
Acetaminophen-CodeineAcetaminophen With Codeine61$1,531
Naproxen31$1,324
Cyclobenzaprine Hcl64$1,094
Hydromorphone Hcl39$884
Oxycodone Hcl59$866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$217$27,48748 claims
Redhill Biopharma Inc.Movantik$13$3,20818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →